Nuveen
ORGO icon

Nuveen’s Organogenesis Holdings ORGO Stock Holding History

Nuveen’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Buy
193,205
+4,460
+2% +$10.9K ﹤0.01% 3304
2026
Q1 		$447K Sell
188,745
-85,230
-31% -$295K ﹤0.01% 2885
2025
Q4 		$1.42M Buy
273,975
+115,890
+73% +$562K ﹤0.01% 2444
2025
Q3 		$667K Hold
158,085
– – ﹤0.01% 2797
2025
Q2 		$579K Sell
158,085
-13,691
-8% -$51K ﹤0.01% 2835
2025
Q1 		$742K Sell
171,776
-166,280
-49% -$671K ﹤0.01% 2760
2024
Q4 		$1.08M Sell
338,056
-436,307
-56% -$1.46M ﹤0.01% 2679
2024
Q3 		$2.21M Buy
774,363
+592,256
+325% +$1.66M ﹤0.01% 2366
2024
Q2 		$510K Hold
182,107
– – ﹤0.01% 2986
2024
Q1 		$517K Hold
182,107
– – ﹤0.01% 2964
2023
Q4 		$745K Sell
182,107
-52,890
-23% -$148K ﹤0.01% 2858
2023
Q3 		$747K Buy
234,997
+53,772
+30% +$171K ﹤0.01% 2691
2023
Q2 		$602K Hold
181,225
– – ﹤0.01% 2867
2023
Q1 		$386K Sell
181,225
-83,320
-31% -$206K ﹤0.01% 2867
2022
Q4 		$712K Sell
264,545
-120,302
-31% -$351K ﹤0.01% 2804
2022
Q3 		$1.25M Sell
384,847
-16,318
-4% -$73.7K ﹤0.01% 2647
2022
Q2 		$1.96M Sell
401,165
-486,136
-55% -$2.99M ﹤0.01% 2443
2022
Q1 		$6.69M Sell
887,301
-218,252
-20% -$1.69M ﹤0.01% 1902
2021
Q4 		$10.1M Buy
1,105,553
+81,588
+8% +$867K ﹤0.01% 1683
2021
Q3 		$17.1M Buy
1,023,965
+103,745
+11% +$1.61M 0.01% 1385
2021
Q2 		$15.3M Sell
920,220
-45,995
-5% -$857K ﹤0.01% 1577
2021
Q1 		$17.6M Buy
966,215
+884,258
+1,079% +$12M 0.01% 1423
2020
Q4 		$617K Buy
81,957
+35,474
+76% +$168K ﹤0.01% 2981
2020
Q3 		$178K Buy
46,483
+483
+1% +$1.91K ﹤0.01% 3172
2020
Q2 		$177K Buy
46,000
+19,740
+75% +$71.2K ﹤0.01% 3116
2020
Q1 		$85K Sell
26,260
-227
-0.9% -$972 ﹤0.01% 3082
2019
Q4 		$127K Hold
26,487
– – ﹤0.01% 3114
2019
Q3 		$174K Hold
26,487
– – ﹤0.01% 3132
2019
Q2 		$201K Buy
+26,487
New +$195K ﹤0.01% 3174

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nuveen's ORGO Position: Q2 2026 in Review

Nuveen increased its Organogenesis Holdings (ORGO) stake by 2.4% in Q2 2026, buying an estimated $10.9K and bringing the position to 193,205 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

Nuveen first reported a position in ORGO in Q2 2019 and has held it in 29 quarters since. The position peaked at $17.6M in Q1 2021. 135 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Nuveen held 193,205 shares of Organogenesis Holdings worth $469K as of Q2 2026.
  • Nuveen bought 4,460 Organogenesis Holdings shares in Q2 2026, an estimated $10.9K.
  • Organogenesis Holdings made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3304 holding.
  • Nuveen first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Organogenesis Holdings position peaked at $17.6M in Q1 2021.
  • 135 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.